Analytical Data
-
Gene name
HLA-A*11:01&B2M&KRAS G12V(VVGAVGVGK) Tetramer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) tetramer recombinant protein is a significant tool in the field of cancer immunology, particularly in understanding the immune response to KRAS mutations, which are commonly implicated in various malignancies, including pancreatic and colorectal cancers. The KRAS G12V mutation leads to aberrant signaling pathways that drive tumorigenesis, making it a critical target for immunotherapeutic strategies. The HLA-A*11:01 molecule is a human leukocyte antigen (HLA) that presents specific peptide antigens to T cells, enabling the immune system to recognize and target cancer cells. By constructing a tetramer that comprises HLA-A*11:01, beta-2 microglobulin (B2M), and the peptide corresponding to the KRAS G12V mutation, researchers can effectively study T cell responses and monitor their activation in response to this mutation. This approach enhances the understanding of both the immune landscape of tumors and the potential for developing targeted immunotherapy, aiming to harness the body’s own immune system to fight cancers harboring the KRAS G12V mutation. The insights gained from this research may contribute to the development of personalized cancer vaccines and novel therapeutic modalities, ultimately improving patient outcomes in cancers associated with KRAS mutations.
